Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer

被引:90
作者
Buller, RE
Sood, AK
Lallas, T
Buekers, T
Skilling, JS
机构
[1] Univ Iowa Hosp & Clin, Dept Obstet & Gynecol, Div Gynecol Oncol, Iowa City, IA 52242 USA
[2] Univ Iowa Hosp & Clin, Dept Pharmacol, Iowa City, IA 52242 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1999年 / 91卷 / 04期
关键词
D O I
10.1093/jnci/91.4.339
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Most human female cells contain two X chromosomes, only one of which is active. The process of X-chromosome inactivation, which occurs early in development, is usually random, producing tissues with equal mixtures of cells having active X chromosomes of either maternal or paternal origin. However, nonrandom inactivation may occur in a subset of females. If a tumor suppressor gene were located on the X chromosome and if females with a germline mutation in one copy of that suppressor gene experienced nonrandom X-chromosome inactivation, then some or all of the tissues of such women might lack the wild-type suppressor gene function. This scenario could represent a previously unrecognized mechanism for development of hereditary cancers. We investigated whether such a mechanism might contribute to the development of hereditary ovarian cancers. Methods: Patterns of X-chromosome inactivation were determined by means of polymerase chain reaction amplification of the CAG-nucleotide repeat of the androgen receptor (AR) gene after methylation-sensitive restriction endonuclease digestion of blood mononuclear cell DNA from patients with invasive (n = 213) or borderline (n = 44) ovarian cancer and control subjects without a personal or family history of cancer (n = 50), BRCA1 gene status was determined by means of single-strand conformational polymorphism analysis and DNA sequencing. All statistical tests were two-sided. Results and Conclusions: Among individuals informative for the AR locus, nonrandom X-chromosome inactivation was found in the DNA of 53% of those with invasive cancer versus 28% of those with borderline cancer (P = .005) and 33% of healthy control subjects (P = .016), Nonrandom X-chromosome inactivation can be a heritable trait. Nine of 11 AR-informative carriers of germline BRCA1 mutations demonstrated nonrandom X-chromosome inactivation (.0002 < P < .008, for simultaneous occurrence of both). Implications: Nonrandom X-chromosome inactivation may be a predisposing factor for the development of invasive, but not borderline, ovarian cancer.
引用
收藏
页码:339 / 346
页数:8
相关论文
共 59 条
[1]  
ALLEN RC, 1992, AM J HUM GENET, V51, P1229
[2]  
[Anonymous], 1987, Am J Obstet Gynecol, V156, P263
[3]  
BELMONT JW, 1994, BLOOD, V84, P2375
[4]   VALUE OF GENETIC VARIANTS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE IN TRACING ORIGIN OF MALIGNANT TUMORS [J].
BEUTLER, E ;
COLLINS, Z ;
IRWIN, LE .
NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (07) :389-&
[5]   Hereditary ovarian cancer: Molecular genetics and clinical implications [J].
Boyd, J ;
Rubin, SC .
GYNECOLOGIC ONCOLOGY, 1997, 64 (02) :196-206
[6]   Role of the X chromosome in cancer [J].
Brown, CJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (08) :480-482
[7]   Field cancerization: Why late "recurrent" ovarian cancer is not recurrent [J].
Buller, RE ;
Skilling, JS ;
Sood, AK ;
Plaxe, S ;
Baergen, RN ;
Lager, DJ .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 178 (04) :641-649
[8]   ABSENCE OF SIGNIFICANT GERM-LINE P53 MUTATIONS IN OVARIAN-CANCER PATIENTS [J].
BULLER, RE ;
SKILLING, JS ;
KALISZEWSKI, S ;
NIEMANN, T ;
ANDERSON, B .
GYNECOLOGIC ONCOLOGY, 1995, 58 (03) :368-374
[9]  
ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO
[10]  
2-Y